Granted Patent
B2
US 12,734,171 · App. 19/257,226 · Granted Sep 15, 2026
Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
Inventors:
John Ford (Cambridgeshire, GB); Patrick Round (Suffolk, GB); John Kastelein (Amsterdam, NL); Atsuhiro Kawaguchi (Osaka, JP); Koichi Tomiyasu (Osaka, JP); Kozo Oka (Osaka, JP)
Assignee:
NEWAMSTERDAM PHARMA B.V.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor: (Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.
Claims (15)
1 . A method of treating hyperlipidemia, hypercholesterolemia, or mixed dyslipidemia, the method comprising:
orally administering 1-25 mg of a compound of formula A
in the form of the free acid or a pharmaceutically acceptable salt thereof,
once daily, with or without food, to a subject who has hyperlipidemia, hypercholesterolemia, or mixed dyslipidemia.
2 . The method of claim 1 , wherein the compound is orally administered in the amount of 5 mg or 10 mg once daily, with or without food.
3 . The method of claim 2 , wherein the compound is orally administered in the amount of 10 mg once daily, with or without food.
4 . The method of claim 3 , wherein the compound is orally administered in a single undivided 10 mg dose, once daily, with or without food.
5 . The method of claim 4 , wherein the compound is orally administered as a single tablet, once daily, with or without food.
6 . The method of claim 5 , wherein the compound is orally administered in the form of the calcium salt, once daily, with or without food.
7 . The method of claim 6 , wherein the compound is orally administered once daily, with or without food, to a subject who has hyperlipidemia.
8 . The method of claim 7 , wherein the compound is orally administered once daily, with or without food, to a subject who has primary hyperlipidemia.
9 . The method of claim 6 , wherein the compound is orally administered once daily, with or without food, to a subject who has hypercholesterolemia.
10 . The method of claim 9 , wherein compound is orally administered once daily, with or without food, to a subject who has primary hypercholesterolemia.
11 . The method of claim 10 , wherein compound is orally administered once daily, with or without food, to a subject who has familial hypercholesterolemia.
12 . The method of claim 6 , wherein the compound is orally administered once daily, with or without food, to a subject who has mixed dyslipidemia.
Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 27, 2026
From: MITSUBISHI TANABE PHARMA CORPORATION
To: DEZIMA PHARMA B.V.
Reel/Frame 073593/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 27, 2026
From: FORD, JOHN; ROUND, PATRICK; KASTELEIN, JOHN
To: DEZIMA PHARMA B.V.
Reel/Frame 073593/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 27, 2026
From: KAWAGUCHI, ATSUHIRO; TOMIYASU, KOICHI; OKA, KOZO
To: MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 073593/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 27, 2026
From: DEZIMA PHARMA B.V.
To: NEWAMSTERDAM PHARMA B.V.
Reel/Frame 074570/0031 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 7, 2025
From: KAWAGUCHI, ATSUHIRO; TOMIYASU, KOUICHI; OKA, KOUZOU
To: MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 071961/0217 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 7, 2025
From: FORD, JOHN; ROUND, PATRICK; KASTELEIN, JOHN
To: DEZIMA PHARMA B.V.
Reel/Frame 071961/0315 →
CHANGE OF NAME
Recorded Aug 7, 2025
From: DEZIMA PHARMA B.V.
To: NEWAMSTERDAM PHARMA B.V.
Reel/Frame 072373/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 7, 2025
From: MITSUBISHI TANABE PHARMA CORPORATION
To: DEZIMA PHARMA B.V.
Reel/Frame 071961/0392 →
Continuity (6)
References Cited (57)
US 7872126B2
· Kubota
· 2011
[cited by examiner]
US 20080269284A1
· Escribano
· 2008
[cited by examiner]
EP 1730152B1
· 2012
[cited by examiner]
JP 2007119450A
· 2007
[cited by examiner]
WO WO2005095409A2
· 2005
[cited by applicant]
Krishna Br J Clin Pharmacol / 68:4 / 535-545, 2009.
[cited by examiner]
Dwivedi, Evergreening: A deceptive device in patent rights, Technology in Society 32 (2010) 324-330.
[cited by examiner]
Feldman, Understanding ‘Evergreening’ : Making Minor Modifications Of Existing Medications To Extend Protections, Health Affairs Jun. 2022 41:6, 801-804.
[cited by examiner]
Zhou, Exploring Ester Prodrugs: A Comprehensive Review of Approaches, Applications, and Methods, Pharmacology & Pharmacy, 2024, 15, 269-284.
[cited by examiner]
Wankhede, Challenges and Strategies in Prodrug Design: A Comprehensive Review, Journal of Advanced Scientific Research, J Adv Sci Res, 2025; 16 (06): 01-20.
[cited by examiner]
“Find ETDs Home ? Thesis Resources? Find ETDs” Online: “https://ndltd.org/thesis-resources/find-etds/” Accessed Jan. 31, 2023.
[cited by applicant]
Ansel et al., “Pharmaceutical Dosage Forms and Drug Delivery Systems”, Lippincott Williams & Wilkins, Seventh Edition, 1999, pp. 48-53.
[cited by applicant]
Barter PJ, Ballantyne CM, Carmena R et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thriy-person/ten-country panel. J Intern Med. 2006;259:247-258.
[cited by applicant]
Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:21009-2122.
[cited by applicant]
Barter PJ, Rye K-A, Beltangady MS et al. Relationship between atorvastatindose and the harm caused by torcetrapib. J Lipid Res. 2012;53:2436-2442.
[cited by applicant]
Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res. 2012;53:1755-1766.
[cited by applicant]
Bartlett “Exploiting Chemical Diversity for Drug Discovery” Edited by Paul A Bartlett and Michael Entzeroth, The Royal Society of Chemistry, 2006, pp. 113-118.
[cited by applicant]
Bloomfield D, Carlson GL, Aditi Sapre BS et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart …
[cited by applicant]
Bochem AE, Kuivenhoven JA, Stroes ESG. The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease. Curr Pharm Des. 2013; 19:3143-3149.
[cited by applicant]
Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;13:1670-1681.
[cited by applicant]
Dansky HM, Bloomfield D, Gibbons P et al. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mix…
[cited by applicant]
Florvall G, Basu S, Larsson A. Apolipoprotein A1 is a stronger prognostic marker than HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men. J Gerontol A Biol Sci Med Sci. 2006;61:1262-1266.
[cited by applicant]
Forrest MJ, Bloomfield D, Briscoe RJ et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increasing circulating levels of aldosterone. Br J Pharmacol. 2008;154:146…
[cited by applicant]
International Search Report and Written Opinion for PCT/NL2014/050068 dated Apr. 4, 2014 (8 pages).
[cited by applicant]
Irwin “ZINC—A Free Database of Commercially Available Compounds for Virtual Screening”, J. Chem. Inf. Model. 2005, 45, 177-182.
[cited by applicant]
Jaeger BR, Richter Y, Nagel E et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc …
[cited by applicant]
Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybj?rg-Hansen A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardio. 2012;60:2041-2048.
[cited by applicant]
Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen city heart study. Circulation. 2008;117:176-184.
[cited by applicant]
Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein(a) and risk of myocardial infarction—genetic epidemiologic evidence of causality. Scand J Clin Lab Invest. 2011;71:87-93.
[cited by applicant]
Kastelein JJP, van Leuven SI, Burgess L et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630.
[cited by applicant]
Kim “PubChem in 2021: new data content and improved web interfaces”, Nucleic Acids Research, 2021, vol. 49, Database issue Published online Nov. 5, 2020.
[cited by applicant]
Krishna R, Bergman AJ, Fallon et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther. 2008;84:67…
[cited by applicant]
Krishna, Garg A, Panebianco D et al. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009;68:535-…
[cited by applicant]
Luscher TF, Taddei S, Kaski JC, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33:857-65.
[cited by applicant]
Marriott et al., “Pharmaceutical Compound and Dispensing”, Second Edition, 2010, pp. 1-288.
[cited by applicant]
Nicholls SJ, Brewer HB, Kastelein JJP et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol. JAMA. 2011;306:2099-2109.
[cited by applicant]
Nicholls SJ, Tuzcu EM, Brennan DM, Tardif J-C, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis. Insights from ILLUSTRATE (Investiga…
[cited by applicant]
Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.
[cited by applicant]
Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203-207.
[cited by applicant]
Ridker PM, Pare G, Parker AN, Zee RYL, Miletich JP, Chasman DI. Circ Cardiovasc Genet. 2009;2:26-33.
[cited by applicant]
Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics—2012 Update: A report from the American Heart Association. Circulation. 2012;125:e12-e230.
[cited by applicant]
Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapibin patients with recent acute coronary syndrome. N Engl J Med. 2012;367:2089-2099.
[cited by applicant]
Simic B, Hermann M, Shaw SG et al. Torcetrapib impairs endothelial function in hypertension. Eur Heart J. 2012;33:1615-1624.
[cited by applicant]
Stein EA, Stroes ES, Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol. 2009;104:82-91.
[cited by applicant]
STN Registry/Zregistry (CAS RegistrySM) Sep. 2016 2 pages.
[cited by applicant]
Thanassoulis G, Campbell CY, Owens DS et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503-512.
[cited by applicant]
The Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA. 2009;302:412-423.
[cited by applicant]
The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
[cited by applicant]
Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RPF, Keavney B, Ye Z, Danesh J. Jama. 2008;299:2777-2788.
[cited by applicant]
Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJP. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: p…
[cited by applicant]
Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-580.
[cited by applicant]
Walldiius G, Jungner I. Rationale for using apolipoprotein B and apolipoproteins A-1 as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J. 2005;26:210-212.
[cited by applicant]